SPHK2 and cancer: Considering that SphK1 and SphK2 are both important therapeutic targets of NSCLC and SKI-349 is a potent SphK1/2 dual inhibitor, the current study explored the potential anti-cancer activity and the possible underlying mechanisms of SKI-349 in NSCLC cells.